MAAT Balance Sheet - Maat Pharma SA - Alpha Spread
M

Maat Pharma SA
PAR:MAAT

Watchlist Manager
Maat Pharma SA
PAR:MAAT
Watchlist
Price: 7.3 EUR 2.24% Market Closed
Market Cap: 101.4m EUR
Have any thoughts about
Maat Pharma SA?
Write Note

Balance Sheet

Balance Sheet Decomposition
Maat Pharma SA

Current Assets 32m
Cash & Short-Term Investments 24.3m
Receivables 5m
Other Current Assets 2.6m
Non-Current Assets 10.9m
Long-Term Investments 200k
PP&E 9.2m
Intangibles 1.3m
Other Non-Current Assets 222k
Current Liabilities 11.5m
Accounts Payable 6.3m
Accrued Liabilities 1.3m
Other Current Liabilities 3.8m
Non-Current Liabilities 10.9m
Long-Term Debt 10.6m
Other Non-Current Liabilities 323k

Balance Sheet
Maat Pharma SA

Rotate your device to view
Balance Sheet
Currency: EUR
Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023
Assets
Cash & Cash Equivalents
4
5
20
43
35
24
Cash
4
5
20
43
17
5
Cash Equivalents
0
0
0
0
19
19
Short-Term Investments
0
0
0
0
0
0
Total Receivables
1
1
2
3
5
5
Accounts Receivables
0
0
0
0
1
0
Other Receivables
0
0
0
3
4
5
Inventory
0
0
0
0
0
0
Other Current Assets
0
0
0
1
2
2
Total Current Assets
5
7
22
47
42
32
PP&E Net
0
0
1
1
1
9
PP&E Gross
0
0
1
1
1
9
Accumulated Depreciation
0
0
0
1
1
2
Intangible Assets
1
1
1
1
1
1
Note Receivable
0
0
0
0
0
0
Long-Term Investments
0
0
0
0
0
0
Other Long-Term Assets
0
0
0
0
0
0
Total Assets
6
N/A
8
+39%
24
+197%
49
+104%
45
-9%
43
-4%
Liabilities
Accounts Payable
1
2
1
2
5
6
Accrued Liabilities
0
0
1
1
1
1
Short-Term Debt
0
0
0
0
0
0
Current Portion of Long-Term Debt
0
1
1
1
3
3
Other Current Liabilities
0
0
0
0
0
0
Total Current Liabilities
2
3
3
5
9
12
Long-Term Debt
2
10
5
5
8
11
Other Liabilities
0
0
0
0
0
0
Total Liabilities
5
N/A
13
+176%
8
-35%
10
+15%
18
+87%
22
+25%
Equity
Common Stock
0
0
1
1
1
1
Retained Earnings
11
5
5
8
13
18
Additional Paid In Capital
12
0
20
46
38
37
Other Equity
0
0
0
0
0
0
Total Equity
1
N/A
5
N/A
16
N/A
40
+150%
27
-33%
20
-24%
Total Liabilities & Equity
6
N/A
8
+39%
24
+197%
49
+104%
45
-9%
43
-4%
Shares Outstanding
Common Shares Outstanding
10
10
10
10
10
12

See Also

Discover More